SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bitcoin (BTC) is a cryptocurrency launched in 2010. Users are able to generate BTC through the process of mining. Bitcoin has a current supply of 20,111,631. The last known price of Bitcoin is 68,229.80907922 USD and is down -4.02 over the last 24 hours. It is currently trading on 12780 active market(s) with $42,739,134,877.94 traded over the last 24 hours. More information can be found at https://bitcoin.org/.

Bitcoin

Bitcoins sharp selloff and pressure on key support levels dominate discussion, with traders speculating about liquidation-driven selling, crypto security fears, and broader market weakness. Bearish traders expect further declines, while bulls describe the move as oversold and a buying opportunity.

XRP (XRP) is a cryptocurrency . XRP has a current supply of 99,985,583,260 with 63,516,606,953 in circulation. The last known price of XRP is 1.0099454 USD and is down -2.36 over the last 24 hours. It is currently trading on 1896 active market(s) with $2,532,309,467.05 traded over the last 24 hours. More information can be found at https://xrpl.org/.

Ripple

A broad crypto-market selloff, which traders say is dragging XRP lower alongside Bitcoin, has fueled concern about further losses; some also point to uncertainty over U.S. crypto legislation and a lack of positive catalysts. The community is split between calls for more downside and dip-buying or accumulation.

Ethereum (ETH) is a cryptocurrency . Ethereum has a current supply of 122,215,668.80579185. The last known price of Ethereum is 1,929.81008702 USD and is down -4.05 over the last 24 hours. It is currently trading on 14342 active market(s) with $15,325,408,368.61 traded over the last 24 hours. More information can be found at https://www.ethereum.org/.

Ethereum

Ethereum is caught in a broad crypto selloff, with traders pointing to Bitcoin weakness, leveraged liquidations and rate-related risk-off sentiment. The community is divided between dip buyers and bears warning of further losses after key support levels gave way.

Hedera (HBAR) is a cryptocurrency launched in 2017. Hedera has a current supply of 50,000,000,000 with 44,327,140,678.86417527 in circulation. The last known price of Hedera is 0.06118377 USD and is down -3.83 over the last 24 hours. It is currently trading on 468 active market(s) with $73,346,897.90 traded over the last 24 hours. More information can be found at https://www.hedera.com/.

Hedera Hashgraph

HBAR is drawing attention amid a sharp decline toward recent lows, with traders debating whether to accumulate the dip or expect further losses. Bears cite weak price performance and concerns about token supply and dilution, while holders argue the pullback is a buying opportunity.

L3Harris Technologies, Inc. engages in the provision of defense and commercial technologies across the air, land, sea, space, and cyber domains. It operates through the following segments: Communication Systems, Integrated Mission Systems, Space and Airborne Systems, and Aerojet Rocketdyne. The Communication Systems segment enables warfighters across all domains with solutions critical to mission success even in the most contested environments. The Integrated Mission Systems segment focuses on the differentiated mission capabilities and prime systems integration for the air, land, and sea domains. The Space and Airborne Systems segment provides full mission solutions as a prime and subsystem integrator in the space, airborne, and cyber domains. The Aerojet Rocketdyne segment includes propulsion, power and armament products and systems to U.S. government, including the DoD, National Aeronautics and Space Administration (“NASA”) and major aerospace and defense prime contractors. The company was founded in 1890 and is headquartered in Melbourne, FL.

L3Harris Technologies Inc

L3Harris is drawing attention after officials and reports linked a nationwide air-traffic communications outage to its contractor-managed network, with the transportation secretary questioning whether installation or router problems were responsible. Traders debate whether L3Harris will face accountability or is being made a scapegoat, while speculation about the causeincluding a possible cyberattackand potential contract shifts adds uncertainty.

Stellar (XLM) is a cryptocurrency launched in 2014. Stellar has a current supply of 50,001,786,837.39707 with 35,407,571,868.045494 in circulation. The last known price of Stellar is 0.14587805 USD and is down -1.99 over the last 24 hours. It is currently trading on 848 active market(s) with $216,910,874.56 traded over the last 24 hours. More information can be found at https://www.stellar.org.

Stellar Lumens

XLM is drawing attention amid a sharp selloff and persistent underperformance, with bearish traders warning of further losses while some holders are buying dips. The community also debates whether Stellars institutional and tokenization developments, including the DTCC connection, can translate into demand for XLM.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summits FDA decision on ivonescimab for EGFR-mutated lung cancer is driving attention, with traders treating the review as a high-stakes binary event. Debate centers on the trials missed prespecified overall-survival significance despite favorable updated survival trends and strong progression-free-survival results: bulls see a case for approval, while skeptics point to the FDAs stated OS requirement and the risk of a rejection or delay.

Terra Classic (LUNC) is a cryptocurrency launched in 2019. Terra Classic has a current supply of 6,443,432,608,476.979021 with 5,520,552,674,073.316941 in circulation. The last known price of Terra Classic is 0.00003691 USD and is down -2.09 over the last 24 hours. It is currently trading on 557 active market(s) with $7,746,116.30 traded over the last 24 hours. More information can be found at https://www.terra-classic.io.

Terra Luna Classic

Speculation that a court case involving Jane Street could lead to a large LUNC burn is fueling hopes for reduced supply and a recovery, alongside chatter about MM2 and rising burns. The outcome is uncertain, and skeptics question whether burns can meaningfully offset the tokens large supply and weak performance.

Dogecoin (DOGE) is a cryptocurrency . Users are able to generate DOGE through the process of mining. Dogecoin has a current supply of 156,738,272,860.16806072. The last known price of Dogecoin is 0.06457313 USD and is down -2.71 over the last 24 hours. It is currently trading on 1545 active market(s) with $672,498,596.98 traded over the last 24 hours. More information can be found at http://dogecoin.com/.

Dogecoin

Dogecoin is drawing attention amid a sharp decline alongside weakness across the broader crypto market, with traders pointing to multiyear lows and debating whether the selloff will deepen. Bearish posts warn of further losses and fading interest, while some holders are buying the dip and expecting a recovery with a future crypto rebound.

Solana (SOL) is a cryptocurrency launched in 2020. Solana has a current supply of 637,493,507.45679271 with 591,519,914.8768357 in circulation. The last known price of Solana is 77.75210106 USD and is down -4.52 over the last 24 hours. It is currently trading on 1189 active market(s) with $3,771,510,230.13 traded over the last 24 hours. More information can be found at https://solana.com.

Solana

Solana is under pressure amid a broad crypto selloff, with traders pointing to Bitcoin weakness and leveraged liquidations as part of the market backdrop. The community is split between calling for further declines and buying or staking the dip.

statis crypto Watchlist

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

QURE Stock Rallies 17.5% in a Month: What Should Investors Do Now? 

uniQure shares rally 17.5% as FDA grants Priority Review to its Huntington's disease gene therapy, but it remains to be seen if clinical and regulatory progress can sustain momentum. 

Kodiak Q3 Loss Wider Than Expected, Pipeline Development in Focus

KOD reports a wider-than-expected Q3 loss, while positive phase III results for Zenkuda and pipeline progress fuel its upcoming regulatory plans.

CRMD Stock Down 9% Despite Q3 Earnings and Revenues Beat Estimates

CorMedix beats Q3 estimates, but DefenCath pricing pressure hurts sales. Rezzayo progress and the planned Heron acquisition shape its 2027 outlook.

ALT Q3 Earnings Miss, Stock Sinks on Higher Costs & Funding Concerns

Altimmune's Q3 loss is wider than estimates as rising R&D costs weigh on earnings, while pemvidutide advances across MASH, AUD and ALD programs.

Here's Why You Should Add AURA Stock to Your Portfolio Now

Aura completes phase III enrollment for bel-sar, with pivotal data expected in 2027 and additional ocular cancer programs expanding its growth potential.

Zoetis' Cytopoint Plus Gets USDA License for 75-Day Canine Itch Relief

ZTS' Cytopoint Plus secures a USDA license, offering dogs with allergic dermatitis 75 days of itch relief and a longer interval between injections.

Pfizer Secures Up to $1.5B Funding From Blackstone for Obesity Program

PFE gets up to $1.5 billion from Blackstone to fund berobenatide's development through 2028, retaining full control of the obesity program.

BEAM Stock Falls 7% Despite Meeting Primary Endpoints in SCD Study

Beam Therapeutics reports positive BEACON study results for risto-cel in sickle cell disease, paving the way for a potential FDA filing by year-end 2026.

LQDA Q3 Earnings Beat Estimates on Robust Yutrepia Sales

Liquidia's Q3 earnings and revenues beat estimates as Yutrepia sales surge, while strong PAH demand and pipeline investments support growth.

MIRM's Brelovitug Scores Second Phase III Win, Nears BLA Filing in HDV

Mirum's brelovitug marks a second phase III win in chronic HDV, bringing the company closer to a planned 2027 BLA filing with the FDA.

Amneal increased full year 2026 net revenue guidance to $3.15B$3.25B, adjusted EBITDA to $800M$815M, and adjusted diluted EPS to $1.04$1.08; operating cash flow guidance was updated to $325M$375M.

Amneal reported a GAAP loss versus prior-year income, nine-month operating cash flow of $50.31M versus $209.68M, net leverage of 3.9x versus 3.5x, and disclosed customer and product concentration risks.

Amneal reported Affordable Medicines and Specialty revenue increases, higher adjusted EBITDA and adjusted diluted EPS, and management cited new launches, a Kashiv integration proceeding well, and biosimilar growth potential.

Amneal Pharmaceuticals, Inc. is a medicine company, which engages in the provision of pharmaceuticals. Its product portfolio includes generics, specialty, biosciences, and product catalog. It operates through the following segments: Generics, Specialty, and AvKARE. The Generics segment relates to oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, and transdermal patches and topicals. The Specialty segment refers to the development, promotion, sale, and distribution of proprietary branded pharmaceutical products. The AvKARE segment provides pharmaceuticals, medical, and surgical products and services to governmental agencies. The company was founded by Chirag K. Patel and Chintu Patel in 2002 and is headquartered in Bridgewater, NJ.

Amneal Pharmaceuticals Inc - Ordinary Shares - Class A

Bullish Sentiment

<ul class="summary-bullets"><li>Ipsen’s Somatuline Depot booked $983 million in U.S. sales in the year through July, according to IQVIA.&nbsp;</li><li>The agency also granted Competitive Generic Therapy status, a label meant to speed copies of drugs that still face thin competition.</li><li>For Amneal, the launch is another hard-to-make injectable in its Affordable Medicines lineup.</li></ul><p><br>Shares of Amneal Pharmaceuticals (AMRX) extended their gains after the closing bell on Friday after the company said the U.S. Food and Drug Administration (FDA) had approved its lanreotide injection and that the product would go on sale immediately.</p><p>The stock closed at $18.71, up 2.35% in regular trading, then rose another 2% after-hours to $19.17 as investors reacted to the long-awaited launch in a market worth almost $1 billion.</p><h2 class="st-heading-2">Green Light, Then An Immediate Start</h2><p>The FDA cleared a 120-milligram prefilled syringe that copies Ipsen’s Somatuline Depot, a long-acting under-the-skin injection. Doctors use it to tame excess growth hormone in acromegaly, slow certain gut and pancreatic neuroendocrine tumors, and ease carcinoid syndrome flare-ups. The agency also granted Competitive Generic Therapy status, a label meant to speed copies of drugs that still face thin competition. Amneal said the product is ready now. Ipsen’s brand booked $983 million in U.S. sales in the year through July, according to IQVIA.</p><p>Rivals are already on the market, such as one made by Cipla’s InvaGen unit.</p><h2 class="st-heading-2">A Date The Company Had Been Circling</h2><p>This was not a sudden win. Amneal’s public pipeline had pointed to a third-quarter 2026 decision. On the July earnings call, co-CEO Chirag Patel said the file had a formal goal date in the quarter and that some sales were already in the forecast, though conservatively.</p><p>For Amneal, the launch is another hard-to-make injectable in its Affordable Medicines lineup, made in company plants rather than farmed out. Srinivas Kone, the unit’s chief scientific officer, said the company can supply the market at scale and use the product as a growth engine.</p><h2 class="st-heading-2">How Did AMRX Retail Traders React?</h2><p>On Stocktwits, retail sentiment around AMRX stock stayed in ‘bearish’ territory over the past 24 hours, while message volume remained ‘high.’</p><p><a href="https://stocktwits.com/symbol/AMRX">AMRX stock</a> has risen 48% year-to-date.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/boeing-starliner-may-get-a-bigger-nasa-role-despite-leaving-crew-behind-as-space-x-looks-past-dragon-says-report/cZtHIQ2RBEf">Boeing Starliner May Get a Bigger NASA Role Despite Leaving Crew Behind As SpaceX Looks Past Dragon, Says Report</a></p><p>For updates and corrections, email newsroom[at]stocktwits[dot]com.</p>

In this photo illustration, the Amneal Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

AMRX Stock Advances As Generic To Ipsen’s Hormone Shot Gets FDA Nod 

The Food and Drug Administration (FDA) cleared a 120-milligram prefilled syringe that copies Ipsen’s Somatuline Depot, a long-acting under-the-skin injection.

AMRX Stock Advances As Generic To Ipsen’s Hormone Shot Gets FDA Nod

Equity

The Food and Drug Administration (FDA) cleared a 120-milligram prefilled syringe that copies Ipsen’s Somatuline Depot, a long-acting under-the-skin injection.


iShares Core S&P Small-Cap ETF

Vanguard Total Stock Market ETF

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '26	$0.24	--	--	N/A
Q3 '26	$0.24	$0.26	9.52%	BEAT
Q2 '26	$0.22	$0.30	34.81%	BEAT
Q1 '26	$0.17	$0.27	59.64%	BEAT
Q4 '25	$0.18	$0.21	14.07%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

AMRX Earnings

Latest Earnings Results: Q3 '26

Historical Earnings